North East and North Cumbria
ICS Formulary
Home
About
Admin
netFormulary
Chapters
Medicines A-Z
News
Mobile
Reports
Feedback
Search
Recent Updates - Updated items
All Formulary Amendments
Records 1 to 10 of 10
Details
LDL
Link Added : NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer : https://www.nice.org.uk/guidance/ta569
25/04/2019 15:08:19
(DavidS )
UPD
Pertuzumab (Perjeta
®
) updated
25/04/2019 15:07:32
(DavidS )
UPD
Published from Draft Mode
31/07/2018 10:23:08
(LoweryM )
LDL
Link Added : NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer : https://www.nice.org.uk/guidance/ta509
30/07/2018 14:31:28
(DavidS )
UPD
Pertuzumab (Perjeta
®
) Addition of approved indication (HER2+ breast cancer) in line with NICE TA509
30/07/2018 14:31:05
(DavidS )
UPD
Pertuzumab (Perjeta
®
) cytotoxic badge removed
25/04/2017 13:44:37
(LoweryM )
UPD
Pertuzumab (Perjeta
®
) cytotoxic badge removed
25/04/2017 13:44:35
(LoweryM )
UPD
Pertuzumab (Perjeta
®
) a
21/04/2017 11:12:05
(DavidS )
LDL
Link Added : NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer : https://www.nice.org.uk/guidance/ta424
31/01/2017 15:59:47
(DavidS )
UPD
Pertuzumab (Perjeta
®
) NICE TA424
31/01/2017 15:59:14
(DavidS )
